Keteks™

Ketorolac Tromethamine

Composition:

Keteks™ 10 mg Tablet: Each film coated tablet contains Ketorolac Tromethamine USP 10 mg.

Keteks™ 30 IM/IV Injection: Each 1 ml ampoule contains Ketorolac Tromethamine USP 30 mg.

Pharmacology:

Keteks™ (Ketorolac) is one of the most potent non-steroidal anti-inflammatory drugs (NSAIDs) yet introduced. It works by blocking the action of cyclo-oxygenase enzyme system, which is involved in the production of prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would cause pain, swelling and inflammation. It may be a useful alternative to the use of opioids.

Indications:

Keteks™ is indicated for the short-term management of moderate to severe acute post-operative pain.

Dosage & administration:

Adult and child over 16 years: By mouth, 10 mg every 4-6 hours (elderly every 6-8 hours); max. 40 mg daily; max. duration of treatment 7 days.

By intramuscular injection *or* by intravenous injection over at least 15 seconds, initially 10 mg, then 10-30 mg every 4-6 hours as required (up to every 2 hours during initial postoperative period); max. 90 mg daily (elderly and patients weighing less than 50 kg max. 60 mg daily); max. duration of treatment 2 days. When converting from parenteral to oral administration, total combined dose on the day of converting should not exceed 90 mg (60 mg in the elderly and patients weighing less than 50 kg) of which the oral component should not exceed 40 mg; patients should be converted to oral route as soon as possible.

Children: Not recommended under 16 years of age.

OR AS DIRECTED BY THE PHYSICIAN.

Contra-indications:

Ketorolac Tromethamine is contraindicated in patients with known hypersensitivity to this drug or other NSAIDs, history of asthma, complete or partial syndrome of nasal polyps,

bronchospasm, history of peptic ulceration or gastrointestinal bleeding, haemorrhagic diatheses (including coagulation disorders) and operations with high risk of haemorrhage or incomplete haemostasis, confirmed or suspected cerebrovascular bleeding, moderate or severe renal impairment, dehydration, pregnancy (including labor and delivery) and breast-feeding.

Warning & precautions:
Ketorolac should be used with caution in heart failure, hepatic impairment and conditions leading to reduction in blood volume or in renal blood flow. The dose of Ketorolac should be reduced in the elderly and in patients weighing less than 50 kg. It is recommended that patients with mild renal impairment should receive a reduced dose of Ketorolac and undergo close monitoring of renal function.

Side effects:
Gastrointestinal discomfort, nausea, diarrhea, ulceration, hypersensitivity reactions, rashes, headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo, anaphylaxis, dry mouth, excessive thirst, psychotic reactions, convulsion, myalgia, hyperkalaemia, bradycardia, hypertension, palpitations, chest pain, post operative wound haemorrhage, etc. may occur.

Use in pregnancy & lactation:
Pregnancy: Ketorolac is contraindicated during pregnancy, labour & delivery.

Lactation: Ketorolac should be avoided during lactation period.

Storage:
Store in a cool and dry place below 30^{o}C, protect from light. Keep out of the reach of children.

Packing:
Keteks™ **10** mg Tablet: Each box contains 30 tablets in blister packs.
Keteks™ **30** IM/IV Injection: Each box contains 5 ampoules in blister pack.

Keteks™ Tablet
Manufactured by:
Jenphar Bangladesh Ltd.
Sreepur, Gazipur, Bangladesh.

Keteks™ IV/IM Injection
Manufactured by
Jenphar Bangladesh Ltd.
Sreepur, Gazipur, Bangladesh.
at Popular Pharmaceuticals Limited
Tongi, Gazipur, Bangladesh.

12002179 Ver.: 01